NCT01814163

Observational Post-authorization Studies Carboplatin, Paclitaxel and Bevacizumab

Observational Studies to Explore the Relation Between Angiogenic Markers and the Treatment Response With Carboplatin, Paclitaxel and Bevacizumab in First Line of Advanced Non-small-cell Lung Cancer With Non- Squamous Histology

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 200 (actual)
• Sponsor: Spanish Lung Cancer Group · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a pharmacogenomic study with carboplatin, paclitaxel and bevacizumab as first line therapy in patients with non-squamous advanced non-small cell lung cancer.

Detailed description

This is a observational study prospectively followed post-authorization.

Conditions

• Nonsquamous Nonsmall Cell Neoplasm of Lung

Interventions

Type	Name	Description
DRUG	paclitaxel, carboplatin and bevacizumab	Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2013-03-19
• Last updated: 2013-03-19

Locations

20 sites across 1 country: Spain